Last reviewed · How we verify
HR
HR is a fixed-dose combination of isoniazid and rifampicin used to treat tuberculosis by inhibiting bacterial cell wall and RNA synthesis.
HR is a fixed-dose combination of isoniazid and rifampicin used to treat tuberculosis by inhibiting bacterial cell wall and RNA synthesis. Used for Tuberculosis (pulmonary and extrapulmonary).
At a glance
| Generic name | HR |
|---|---|
| Also known as | isoniazid, H, rifampicin, R |
| Sponsor | Global Alliance for TB Drug Development |
| Drug class | Anti-tuberculosis agent (fixed-dose combination) |
| Target | Mycobacterial cell wall (isoniazid) and bacterial RNA polymerase (rifampicin) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Isoniazid inhibits mycolic acid synthesis in the mycobacterial cell wall, while rifampicin inhibits bacterial RNA polymerase. Together, these first-line anti-tuberculosis agents provide synergistic bactericidal activity against Mycobacterium tuberculosis. The combination is a standard component of TB treatment regimens.
Approved indications
- Tuberculosis (pulmonary and extrapulmonary)
Common side effects
- Hepatotoxicity
- Peripheral neuropathy
- Gastrointestinal disturbance
- Rash
- Drug-induced lupus
Key clinical trials
- Exemption of SLNB After Neoadjuvant Therapy for Triple-negative and Her2-positive Breast Cancer (NA)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients (PHASE3)
- Sphenopalatine Ganglion Block for Post-Dural Puncture Headache: A Pilot Randomised Controlled Trial (NA)
- Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors (PHASE1)
- A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) (PHASE3)
- Epidemiology and Treatment of HR+/HER2- Breast Cancer in England
- Blood Flow Restricted Resistance Exercises Versus Low Level Laser on Cardiac Functions in Patients With Chronic Heart Failure (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HR CI brief — competitive landscape report
- HR updates RSS · CI watch RSS
- Global Alliance for TB Drug Development portfolio CI